21177 WEBCAST: The Latest Advances in Treatment of GvHD: Where Are We and Where Are We Going?
Graft-versus-host disease (GvHD) is the most common cause of life-threatening complications following allogeneic hematopoletic stem cell transplantation (allo-HSCT). Acute GvHD is the second leading cause of death, after disease relapse, in patients undergoing allo-HSCT, Chronic GvHD is often preceded by acute GvHD and occurs in 30% to 70% of patients. Prophylaxis regimens show promise in improving clinical outcomes in patients with allo-HSCT-related complications, and therapies targeting Janus Kinase 1/2 and Bruton's tyrosine kinase have demonstrated effectiveness in both acute and chronic GvHD. Biomarkers have the potential to significantly improve a physician's ability to determine risk for patients who have undergone allo-HSCT, who have not yet developed GvHD and aid in evaluating patient response to GvHD therapy. As new data in GvHD therapies are reported, hematologists need to receive education and support on how best to incorporate new strategies into their practice.
In this CME activity, 3 faculty experts in GvHD discuss recent advances in therapies for acute and chronic GvHD, as well as prophylactic treatment strategies, and present a case study that highlights the incorporation of biomarker data into the care of patients with GvHD. In their discussion, they share their experiences in caring for patients with GvHD provide insight into clinical trial data, and offer strategies for integrating new therapeutic approaches into clinical practice.
This activity can be accessed using the following URL: https://education.gotoper.com/activity/tct-gvhd21-prerecord
- Medical Oncologists
- Investigators who treat or are interested in the treatment of patients with hematologic malignancies
- Other allied healthcare professionals (Nurse Practitioners, Physician Assistants, and Nurses involved in the treatment and management of patients with hematologic malignancies
- Summarize recent advances to understand the mechanisms that underline GvHD development to better inform clinical decision-making
- Integrate current approaches for the prophylaxis and treatment of GvHD into clinical practice
- Explain unmet clinical needs in GvHD management and the role of emerging approaches and therapies to bridge these gaps in care
This activity is supported by an educational grant from Incyte Corporation
In accordance with ACCME Guidelines, PER® has no relevant financial relationships with ineligible entities.
James L.M. Ferrara, MD, DSc
Ward-Coleman Chari in Cancer Medicine
Professor and Director
Hematologic Malignancies Translational Research Center
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Consultant Eurofins Viracor: other: Royalties from Eurofins Viracor
Professor Ernest Holler, MD, PhD
Senior Professor on Allogeneic Stem Cell Transplantation
Former Director of the Allogeneic Stem Cell Transplantation Program
Department of Internal Medicine IIII (Hematology & Oncology)
University of Regensburg
Disclosures: Grant Research Support: Medac Germany, Consultant: MaajT Pharma, France; Medac German; Novartis: speaker Bureau Jazz Pharmaceuticals Neovii
Carrie Lynn Kitko, MD
Associate Professor of Pediatrics
Ingram Professorship in Pediatric Oncology
Medical Director, Pediatric Stem Cell Transplantation Program
Vanderbilt University Medical Center
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PER, Physician Education Resource, LLC. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This CME activity is jointly provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.